Английская Википедия:GLY-200

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Orphan

GLY-200 is an experimental drug that acts as a "polymeric mucin binding duodenal exclusion therapy"; it is developed by Glyscend Therapeutics for type 2 diabetes and obesity. It is intended to reversibly mimic the effects of gastric bypass without the need for surgery. The drug is not absorbed into the body from the gut and has been tested as monotherapy and with metformin.[1][2][3][4][5][6]

References

Шаблон:Reflist

  1. Significant Weight Loss Due to a Novel Oral Polymeric Mucin Binding Duodenal Exclusion Therapy Nimgaonkar, Ashish, MD; Sanglard, Larissa, MD; Habegger, Kirk, PhD; Colbert, Kevin, MS; Carlson, Taylor, PhD; et al.  Obesity; Silver Spring Vol. 29, (Dec 2021): 162.
  2. A First-in-Human Study of GLY-200, an Oral, Gut- Restricted, Pharmacologic Duodenal Exclusion Therapy Fineman, Mark, PhD; Bryant, Christine, PhD; Colbert, Kevin, MS; Jozefiak, Thomas, PhD; Petersen, John, PhD; et al.  Obesity; Silver Spring Vol. 30, (Nov 2022): 19.
  3. Шаблон:Cite journal
  4. Шаблон:Cite news
  5. Шаблон:Cite journal
  6. Шаблон:Cite journal